FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | | 0.0000025 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | | 0.0000025 USD | | 50,000 | 本月 ...

Market Performance - Hang Seng Index fell by 403 points, or 1.6%, closing at 24,773 points[1] - Shanghai Composite Index dropped by 42 points, or 1.18%, closing at 3,573 points[2] - S&P 500 decreased by 23 points, or 0.4%, closing at 6,339 points, marking the third consecutive day of decline[2] Currency and Economic Indicators - Hong Kong Monetary Authority bought HKD 39.25 billion during New York session due to a weak HKD[1] - People's Bank of China conducted a 7-day reverse repo operation of CNY 283.2 billion at a steady rate of 1.4%[2] - July's official manufacturing PMI in China fell to 49.3, below expectations[2] Real Estate and Corporate Performance - Top 100 real estate companies in China reported total sales of CNY 2.07 trillion in the first seven months, a year-on-year decline of 13.3%[4] - Internet and related services companies in China generated revenue of CNY 961.3 billion in H1, a year-on-year growth of 3.1%[4] - Sinopec expects H1 2025 net profit to be between CNY 20.1 billion and CNY 21.6 billion, a year-on-year decline of 39.5% to 43.7%[6] Automotive Sector - XPeng Motors delivered 36,717 smart electric vehicles in July, a year-on-year increase of 229%[7] - Cumulative deliveries exceeded 800,000 units as of July, with a total of 233,906 units delivered in the first seven months, marking a 270% year-on-year growth[7]

港股异动｜药师帮(09885)盈喜后涨超3% 预计中期股东应占利润不少于7000万元 本文源自智通财经网 消息面上，7月31日，药师帮发布公告，预期截至2025年6月30日止半年度公司拥有人应占利润将不少于 人民币7000万元，为截至2024年6月30日止半年度公司拥有人应占利润人民币2180万元的3倍以上。 董事会认为，集团上述预期利润增加主要得益于以下原因：(集团凭着稳固的行业领先地位及竞争优 势，持续保持收入的稳健增长；集团自有品牌产品的下游需求持续保持旺盛，该高毛利率的业务规模持 续增长，不断提升公司的毛利率水平；集团拥有扎实的科技底座，通过数字化能力的不断提升，带动核 心的平台和自营业务的运营效率不断提升。 金融界 智通财经获悉，药师帮(09885)盈喜后涨超3%，截至发稿，涨3.31%，报10.6港元，成交额1829.01万港 元。 ...

董事会认为，集团上述预期利润增加主要得益于以下原因：(集团凭着稳固的行业领先地位及竞争优 势，持续保持收入的稳健增长；集团自有品牌产品的下游需求持续保持旺盛，该高毛利率的业务规模持 续增长，不断提升公司的毛利率水平；集团拥有扎实的科技底座，通过数字化能力的不断提升，带动核 心的平台和自营业务的运营效率不断提升。 药师帮(09885)盈喜后涨超3%，截至发稿，涨3.31%，报10.6港元，成交额1829.01万港元。 消息面上，7月31日，药师帮发布公告，预期截至2025年6月30日止半年度公司拥有人应占利润将不少于 人民币7000万元，为截至2024年6月30日止半年度公司拥有人应占利润人民币2180万元的3倍以上。 ...

智通财经APP获悉，药师帮(09885)盈喜后涨超3%，截至发稿，涨3.31%，报10.6港元，成交额1829.01万 港元。 消息面上，7月31日，药师帮发布公告，预期截至2025年6月30日止半年度公司拥有人应占利润将不少于 人民币7000万元，为截至2024年6月30日止半年度公司拥有人应占利润人民币2180万元的3倍以上。 董事会认为，集团上述预期利润增加主要得益于以下原因：(集团凭着稳固的行业领先地位及竞争优 势，持续保持收入的稳健增长；集团自有品牌产品的下游需求持续保持旺盛，该高毛利率的业务规模持 续增长，不断提升公司的毛利率水平；集团拥有扎实的科技底座，通过数字化能力的不断提升，带动核 心的平台和自营业务的运营效率不断提升。 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company is expected to achieve a net profit attributable to shareholders of no less than RMB 70 million in the first half of 2025, which is more than three times the RMB 21.8 million net profit from the same period last year [1] - The high growth in performance is attributed to "scale effects + high gross margin business + digital empowerment" [4] - The company's self-owned brand products continue to see strong downstream demand, contributing to the growth of high-margin business and improving overall gross margin [4] - The strategic flagship product, Huoxiang Zhengqi Oral Liquid, has shown strong sales performance, with a peak daily sales exceeding RMB 5 million [4] - The company is expected to maintain high growth in the second half of 2025, driven by self-owned brands, AI, robotics, and stock buybacks [4][5] Financial Summary - The company’s total revenue is projected to be approximately RMB 20.83 billion, RMB 23.51 billion, and RMB 26.70 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 16%, 13%, and 14% [6][7] - The net profit attributable to shareholders is expected to be RMB 1.49 billion, RMB 3.20 billion, and RMB 5.50 billion for the same years, with year-on-year growth rates of 395%, 116%, and 71% [6][7] - The gross margin is projected to improve from 10.89% in 2025 to 11.82% in 2027 [6] - The return on equity (ROE) is expected to increase from 6.14% in 2025 to 16.68% in 2027 [6] - The earnings per share (EPS) is projected to rise from RMB 0.22 in 2025 to RMB 0.81 in 2027 [6]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

本文源自：金融界AI电报 药师帮(09885.HK)发布公告，预期截至2025年6月30日止半年度公司拥有人应占利润将不少于人民币 7000万元，为截至2024年6月30日止半年度公司拥有人应占利润人民币2180万元的3倍以上。 ...

上半年业绩的持续增长，得益于公司"向上走"战略的夯实推进。今年上半年，药师帮加速拓展首推业 务，不断扩充「乐药师」等自有品牌产品阵营，进一步提升公司的供给能力及运营能力，实现高毛利、 高附加值业务的增长提速。其中，战略单品藿香正气口服液上半年单日销售峰值一度突破500万元，在 济南、潍坊等地日均销量持续突破1000盒，展现出自有品牌在多线级市场的渗透能力；在第三终端的销 售占比达41.2%，较去年提升6.2个百分点，基层医疗覆盖取得突破性进展；新增买家约40,000家，消费 者黏性持续强化。 智通财经APP获悉，7月31日，药师帮（09885）于港交所发布盈喜公告。公告显示，公司今年上半年净 利润预期将不少于人民币7000万元，为上年同期3.2倍以上。公司延续2024年扭亏为盈的强劲势头，发 力自有品牌业务、供应链效率优化及基层医疗生态扩张，驱动业绩再创新高。 多家机构观点表示，药师帮已进入盈利加速释放期。其中，信达证券预测公司2025年归母净利润将达 1.49亿元，同比增幅高达395%，2026年有望进一步增长116%至3.2亿元。据行业测算，中国院外医药数 字化流通市场规模将在2027年达到3583亿元， ...

公开数据显示，药师帮2024年实现营收179.04亿元，同比增长5.5%；净利润首度转正至3001万元，经营 性现金流净流入同比大增45%至6.56亿元。今年上半年，公司业绩继续维持高增长态势：1-4月，厂牌首 推业务交易规模达7.17亿元，较上年同期猛增108.1%，其中自有品牌业务贡献5.6亿元，同比激增 532.3%。供应链效能持续领跑行业，存货周转33.4天，现金循环周期优化至负31.5天，"快周转+现金 牛"优势突出，财务基本面持续优化。 上半年业绩的持续增长，得益于公司"向上走"战略的夯实推进。今年上半年，药师帮加速拓展首推业 务，不断扩充"乐药师"等自有品牌产品阵营，进一步提升公司的供给能力及运营能力，实现高毛利、高 附加值业务的增长提速。其中，战略单品藿香正气口服液上半年单日销售峰值一度突破500万元，在济 南、潍坊等地日均销量持续突破1000盒，展现出自有品牌在多线级市场的渗透能力；在第三终端的销售 占比达41.2%，较去年提升6.2个百分点，基层医疗覆盖取得突破性进展；新增买家约40,000家，消费者 黏性持续强化。 7月31日，药师帮(09885)于港交所发布盈喜公告。公告显示，公司今年 ...